Dr. Rene Bruno Will Present on the Value of Clinical Trial Simulations to
Predict Efficacy and Survival Benefit of Anticancer Agents
MOUNTAIN VIEW, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Rene Bruno, Ph.D., managing director, Strategic Consulting Services, Europe, has been invited to speak to academics, regulators, and members of the Chinese pharmaceutical industry attending the International Symposium in Quantitative Pharmacology in Drug Development and Regulation. The symposium will be held in Nanjing China at the International Conference Hotel from October 29-31, 2007.
Dr. Bruno will join other leading experts from industry, government and academia in a scientific program that will discuss the latest methodologies in pharmacometrics, focusing on pharmacokinetic and pharmacodynamic (PK/PD) modeling and simulation in drug development, regulation and clinical applications. The symposium will also provide a forum for scientific discussion and collaborative exchange on model-based approaches in drug development. Dr. Bruno's presentation, discussing a model-based approach to support drug development in oncology, will be part of a session focusing on the theory and applications of model-based drug development. The presentation, entitled "Clinical Trial Simulations to Predict Efficacy and Survival Benefit of Anticancer Agents", will take place on October 29, 2007. Dr. Bruno also serves on the symposium's international advisory committee.
"Model-based drug development continues to grow as a value-added method
for optimizing decisions in the drug development process," said Shawn
O'Connor, president, CEO, and chairman of Pharsight. "Drug development is
benefiting from the quantitative application of drug-disease models to
simulate expected clinical re
|SOURCE Pharsight Corporation|
Copyright©2007 PR Newswire.
All rights reserved